 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
 |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
2009 |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
A Physiologically-Based Mathematical Model to Predict Lung Retention and Inhaled Pharmacokinetics of Therapeutic Candidates | 2/26/2009 2:58:34 PM | Poster: Methodology- PBPK | |
PulmoSim: A Physiologically-Based Mathematical Model Software Package to Predict Lung Retention and Inhaled Pharmacokinetics of Therapeutic Candidates | 2/26/2009 3:07:23 PM | Software demonstration | |
A4S: a user-friendly PKPD simulation software for non experts | 4/20/2009 7:36:57 PM | Software demonstration | |
Population Pharmacokinetics of Midazolam and Metabolites during Venoarterial Extracorporeal Membrane Oxygenation in Neonates | 2/27/2009 4:57:13 PM | Poster: Applications- CNS | |
Population PK-PD Modelling of Wheal and Flare Area in a First-Time-in-Human Study | 3/13/2009 3:08:39 PM | Poster: Applications- Other topics | |
Population TK/TD for chemical risk assessment and drug safety: the cadmium example | 3/5/2009 9:16:01 AM | Oral Presentation: Other topics | |
Are Children Small Adults? | 6/10/2009 8:39:01 AM | Oral Presentation: Pediatrics | |
Antic J. (1,2), Chenel M. (2), Laffont C. M. (1), Concordet D. (1). | Nonparametric Methods: When to use them? Which method to choose? | 2/27/2009 9:33:15 AM | Oral Presentation : Lewis Sheiner Student Session |
PDx-Pop® 4 for NONMEM® 7 | 4/7/2009 9:17:43 PM | Software demonstration | |
KT. Baron, AK. Birnbaum, JC. Cloyd, J. St. Peter, and RC. Brundage | Evaluation of Assumptions in the Clinical Use of the Cockcroft-Gault Equation | 3/15/2009 7:03:30 PM | Poster: Applications- Other topics |
Improvements and New Estimation Methods in NONMEM 7 for PK/PD Population Analysis | 3/12/2009 5:42:05 PM | Oral Presentation: Methodology | |
Two PsN Bootstrapping Routines for Obtaining Uncertainty Measurement around the Nonparametric Distribution Obtained in NONMEM VI | 3/12/2009 6:30:46 PM | Poster: Methodology- Other topics | |
Prediction of power of test of discrete covariates in population analyses and influence of design: application to gender effect in joint pharmacokinetic models of nucleoside analogs and their active metabolites | 3/15/2009 4:24:05 PM | Poster: Methodology- Design | |
New features for population design evaluation and optimization with R functions: PFIM Interface 3.1 and PFIM 3.2 | 3/14/2009 9:45:15 AM | Software demonstration | |
Whole-Body Physiologically-Based Pharmacokinetic (WB-PBPK) Modeling of Moxifloxacin (MFX) to Support a Translational Approach in Pediatric Study Design | 3/13/2009 3:53:54 PM | Poster: Methodology- PBPK | |
An Efficiency Comparison between Concentration-Response Analysis and Dose-Response Analysis through Simulation | 3/11/2009 3:24:30 PM | Poster: Methodology- Other topics | |
Semi-mechanistic PK/PD modeling of Paracetamol and Sulfapyridine to characterize effects on gastric emptying and small intestinal transit | 3/15/2009 9:18:27 PM | Poster: Applications- Other topics | |
Visual Predictive Checks for Censored and Categorical data | 3/14/2009 5:24:23 PM | Poster: Methodology- Model evaluation | |
Bertrand J (1), Comets E (1), Laffont CM (2), Chenel M (3), Mentré F (1) | Model-based tests to detect gene effect in pharmacokinetic studies | 3/1/2009 2:07:49 AM | Oral Presentation: Methodology |
Bizzotto R (1), Zamuner S (2), De Nicolao G (3), Cobelli C (1), Gomeni R (2) | Multinomial logistic functions in Markov-chain models for modelling sleep architecture after placebo administration | 3/9/2009 12:12:03 PM | Poster: Applications- CNS |
A two-compartment effect site model describes the Bispectral Index Score (BIS) after administration of propofol | 3/14/2009 11:38:46 AM | Poster: Applications- CNS | |
Population Pharmacokinetics of Carbamazepine and Estimation of Influencing Factors | 3/11/2009 8:17:27 PM | Poster: Applications- CNS | |
External Validation of the Population Models for Carbamazepine Pharmacokinetics and the Individualizing Carbamazepine Dosage Regimen Procedure | 3/13/2009 6:50:32 PM | Poster: Applications- CNS | |
Relating Pharmacokinetics and Pharmacodynamics of Proton Pomp Inhibitors (PPIs) to Clinical Performance in Patients with Gastroesophageal Reflux Disease (GERD) | 3/13/2009 3:59:47 PM | Poster: Applications- Other topics | |
M.A. Boroujerdi (1), C. van Kesteren (1), A. Facius (2), M. Danhof (1), O.E. Della Pasqua (1,3) | A turnover longitudinal model for the analysis of FEV1 changes in COPD | 3/13/2009 3:07:37 PM | Poster: Methodology- Other topics |
Lorea Bueno1, Dinesh P de Alwis2, Colin Miles2, Sophie Glatt2, and Iñaki F. Trocóniz1 | Semi-Mechanistic Modelling of the Tumour Growth Inhibitory Effects of a New Anti-angiogenic Drug. | 3/4/2009 5:38:04 PM | Poster: Applications- Oncology |
Massimo Cella(1), Frank Kloprogge(1), Meindert Danhof(1) and Oscar Della Pasqua(1,2) | Scaling of fixed-dose combinations in children | 3/15/2009 1:17:38 PM | Poster: Methodology- Design |
Not-In-Trial Simulation: Predicting cardiovascular risk from clinical trial data | 3/12/2009 4:38:36 PM | Poster: Applications- CVS | |
P. L. S. Chan (1), P. Jacqmin (2), M. Lavielle (3), L. McFadyen (1), B. Weatherley (1) | Population Pharmacokinetic-Pharmacodynamic-Viral Dynamics Modelling of Maraviroc Monotherapy Data Using MONOLIX | 3/12/2009 5:45:04 PM | Poster: Methodology- Other topics |
Concentration-Response Modelling of Adjunctive Lamotrigine Extended-Release for Primary Generalised Tonic-Clonic Seizures | 3/14/2009 2:03:02 PM | Poster: Applications- CNS | |
S.Y. Amy Cheung (1), Malcolm Rowland (2), Leon Aarons (2), Trudy Rodgers (1), Iva Gueorguieva (3) | Development of a closed loop whole body (WB) physiologically based pharmacokinetic model (PBPK) of beta-blockers in the rat | 3/14/2009 4:04:32 PM | Poster: Methodology- PBPK |
Enhanced quantitative drug development (EQDD) of a selective PDE5 inhibitor for the treatment of benign prostatic hyperplasia (BPH) | 6/2/2009 9:14:11 AM | Poster: Applications- Other topics | |
A bibliographic review of non-parametric methods and their application | 3/15/2009 10:07:26 PM | Poster: Methodology- Algorithms | |
Damien Cronier (2), Lawrence Gelbert(1), Graham Wishart (2), Alfonso De Dios (1) | A fully integrated PK/IVTI/IVE model in mouse to help design the FHD trial for a cell cycle inhibitor X | 3/14/2009 10:17:29 PM | Poster: Applications- Oncology |
Population pharmacokinetics of voriconazole in patients with invasive mycoses | 3/13/2009 5:49:28 PM | Poster: Applications- Anti-infectives | |
Population pharmacokinetic analysis of pramipexole extended-release formulation in Parkinson’s Disease (PD) patients | 3/13/2009 9:07:18 AM | Poster: Applications- CNS | |
Issues of size and scaling in comparative biology | 6/10/2009 8:37:12 AM | Oral Presentation: Pediatrics | |
Mechanism-based pharmacokinetic modelling of protein binding of mycophenolic acid and its glucuronide metabolite in renal transplant recipients | 2/26/2009 4:53:03 PM | Poster: Methodology- PBPK | |
W. de Winter(1), S. Rossenu (1), A. Dunne (1), A. Vermeulen (1) | Integrating a Model for Weight Change into the Mechanism-Based Model for Type 2 Diabetes | 3/16/2009 2:36:47 AM | Oral Presentation: Clinical Applications |
Application of pharmacokinetic-pharmacodynamic model to optimize dosing regime of antimicrobial drug Grammidin containing gramicidin S | 5/8/2009 10:41:08 AM | Poster: Applications- Anti-infectives | |
Modeling and Simulation for Determination of the Therapeutic Window of MK-2295: a TRPV1 Antagonist | 3/12/2009 2:27:51 PM | Oral Presentation: Clinical Applications | |
Paolo Denti (1), Alessandra Bertoldo (1), Paolo Vicini (2,3), Claudio Cobelli (1) | Covariate Selection for the IVGTT Minimal Model of Glucose Disappearance | 3/15/2009 9:16:54 PM | Poster: Applications- Endocrine |
A NonLinear Mixed-Effects Approach to the Estimation of the Glucose Disposition Index | 3/15/2009 10:24:15 PM | Poster: Applications- Endocrine | |
Prediction of a Metabolic Drug-Drug Interaction in a Virtual Human Population using in vitro Enzyme Kinetic Information | 3/5/2009 11:24:47 AM | Poster: Methodology- PBPK | |
Sven Mensing, Peter Nörtersheuser, Paul-Matthias Diderichsen | Markov Modeling of Side Effect Related Dropout Rates by Introduction of Previous State Memory | 6/16/2009 1:09:44 PM | Poster: Applications- Other topics |
Population pharmacokinetics and pharmacodynamics of Propofol in morbidly obese patients | 3/14/2009 8:54:06 PM | Poster: Applications- CNS | |
Initial Estimates for Parameter Estimation | 3/13/2009 4:36:28 PM | Poster: Methodology- Algorithms | |
ADAS-Cog Placebo Modelling in Alzheimer’s Disease | 3/12/2009 5:13:45 PM | Poster: Applications- CNS | |
A. Dubois (1), M. Lavielle (2), S. Gsteiger (3), E. Pigeolet (3) and F. Mentré (1) | Extension of the SAEM algorithm and evaluation of Wald and likelihood ratio tests for interaction or bioequivalence studies | 3/12/2009 1:09:22 PM | Poster: Methodology- Algorithms |
Parameterization of a physiologically-based pharmacokinetic (PBPK) model for the simulation of ibuprofen pharmacokinetics under exercise and heat stress with validation from clinical data | 3/19/2009 9:21:28 PM | Poster: Methodology- PBPK | |
Variability as constant coefficient of variation: Can we right two decades in error? | 3/12/2009 2:52:21 PM | Poster: Methodology- Other topics | |
C. Steven Ernest II(1,2), Andrew Hooker(1) and Mats O. Karlsson(1) | Improved parameter estimation and design optimization for In Vitro ligand binding experiments | 3/13/2009 3:47:55 PM | Poster: Methodology- Algorithms |
A.-L. FLAUGERE(1), M. CARLES(2), E. RAMAIN (2), A. BOULAMERY-VELLY(1), N. SIMON(1) | Population pharmacokinetics of imipenem bone concentrations in pigs | 3/11/2009 5:28:10 PM | Poster: Applications- Anti-infectives |
Modelization of bevacizumab effect on tumour perfusion assessed by Dynamic Contrast Enhanced Ultrasonography | 3/13/2009 1:52:22 PM | Poster: Applications- Oncology | |
Population pharmacokinetic model development and evaluation after nevirapine administration to mothers and newborns | 3/10/2009 5:38:30 PM | Poster: Applications- Anti-infectives | |
Jonathan L. French (1), Neal Thomas (2), Sriram Krishnaswami (3), Gary Chan (4) | Safety monitoring of a kidney transplant study using a Bayesian time-to-event model | 3/15/2009 6:58:43 PM | Poster: Applications- Other topics |
Population model of Human Chorionic Gonadotropin to predict resistance in low risk gestational trophoblastic neoplasia patients | 3/13/2009 11:51:35 AM | Poster: Applications- Oncology | |
Daniel Moreno1, Sara Zalba1, Iñigo Navarro2, Conchita Tros1, Iñaki F. Trocóniz1, María J Garrido1 | Pharmacokinetics and antitumor efficacy characterization of cisplatin-loaded PLGA nanoparticles in tumor-bearing mice. | 3/15/2009 11:06:54 PM | Poster: Applications- Oncology |
Link between cyclosporin exposure in tissues and graft versus host disease in paediatric bone marrow transplantation: analysis by a PBPK model | 3/14/2009 8:53:31 PM | Poster: Methodology- PBPK | |
Influence of cyclosporin infusion duration on efficacy in paediatric bone marrow transplantation: analysis by a PBPK model | 3/14/2009 8:47:42 PM | Poster: Methodology- PBPK | |
Pharmacodynamic Modeling of Biologics with Target-Mediated Drug Disposition: TMDD Approximations, Relation to Indirect-Response Models, and Application to Population PK-PD Analyses | 3/7/2009 10:44:21 PM | Poster: Methodology- Other topics | |
Population Pharmacokinetics of AMG 317, a Fully Human Anti-IL-4Rα IgG2 Monoclonal Antibody Evaluated in Healthy and Asthmatic Subjects | 3/13/2009 3:00:02 AM | Poster: Applications- Biologicals/vaccines | |
Ekaterina Gibiansky (1), Jianping Zhang (2), Daphne Williams (3), Zhao Wang (1), Daniele Ouellet (2) | Population Pharmacokinetics of Eltrombopag in Healthy Subjects and Patients with Chronic Idiopathic Thrombocytopenic Purpura | 3/12/2009 1:20:59 AM | Poster: Applications- Coagulation |
Comparison of different tools for the optimization of a pediatric clinical trial | 3/15/2009 8:27:53 PM | Oral Presentation: Design | |
Target-Mediated Drug Disposition Model to Describe Non-linear Kinetics of a Monoclonal Antibody | 4/9/2009 12:08:09 PM | Poster: Applications- Biologicals/vaccines | |
Varun Goel (1), Timothy E Hanson (2), Brian Corrigan (3), Raymond Miller (3), Richard C Brundage (1) | A Bayesian Multivariate Model for Repeated Measures of Correlated Data | 3/14/2009 11:40:05 PM | Poster: Methodology- Other topics |
S. Goutelle (1,2), L. Bourguignon (1,2), N. Bleyzac (1,3), P. Maire (1,2), R.W. Jelliffe (4) | Performing Monte Carlo Simulation Based on Nonparametric Pharmacokinetic Parameter Distributions: Evaluation of Various Methods Applied to a Paediatric Population Study on Busulfan | 3/12/2009 10:32:03 PM | Poster: Methodology- Other topics |
Population Pharmacokinetics of the Active Metabolite of Leflunomide in Patients with Rheumatoid Arthritis | 3/14/2009 11:50:51 PM | Poster: Applications- Other topics | |
Ted Grasela, Julie Passarell, Elizabeth Ludwig, Jill Fiedler-Kelly | Modeling and Simulation Approach to Pediatric Drug Development | 3/13/2009 9:53:00 PM | Poster: Methodology- Design |
Thaddeus Grasela* (1), Jill Fiedler-Kelly (1), Darcy Hitchcock (1) | Improving the Efficiency and Ensuring the Quality of Data Assembly for Pharmacometric Analysis | 3/13/2009 3:37:14 PM | Poster: Applications- Other topics |
Ivelina Gueorguieva, Kimberley Jackson, Steven A. Wrighton, Vikram P Sinha and Jenny Y. Chien | Desipramine Population Pharmacokinetic Model and Designing CYP2D6 Drug-Drug Interaction Studies | 3/5/2009 3:07:51 PM | Poster: Methodology- Design |
M.Guery (1), G.Herbin (1), C.Pobel (1), E.Kiep (1), C.Donamaria (2) | Data mining analysis of survival data in cancer of pancreas : first exploratory step for identification and validation of explicative variables | 3/13/2009 6:57:14 PM | Poster: Applications- Oncology |
AK Hamberg (1)(4), JD Lindh (2), M Wadelius (1), A Rane (2) ML Dahl (1), EN Jonsson (3)(5) | A longitudinal model describing the relationship between warfarin dose and INR response taking CYP2C9, VKORC1 and age into account | 3/10/2009 10:18:03 PM | Poster: Applications- Coagulation |
Pharmacokinetic-Pharmacodynamic Modeling of the Angiogenic Factors VEGF, sVEGFR-2, sVEGFR-3 and sKIT following Sunitinib Treatment in GIST | 3/12/2009 6:59:53 PM | Poster: Applications- Oncology | |
Population PK of Sildenafil and PK/PD assessment of Exercise tolerability in children with Pulmonary Arterial Hypertension (PAH) | 3/12/2009 7:52:49 PM | Oral Presentation: Pediatrics | |
Siobhan Hayes (1), Daniele Ouellet (2), Jianping Zhang (2), Mary Wire (2), Ekaterina Gibiansky (1) | Population PK/PD Modeling of Eltrombopag in ITP Patients and Optimization of Response-Guided Dosing | 3/13/2009 12:44:16 PM | Poster: Applications- Coagulation |
G. Kersting (1,2), S. Willmann (3), G. Würthwein (2), J. Lippert (3) , J. Boos (2), G. Hempel (1,2) | Physiologically-Based Pharmacokinetic (PBPK) Model for High- and Low Dose Etoposide: From Adults to Children | 3/13/2009 4:47:03 PM | Poster: Applications- Oncology |
Tablet position in gastrointestinal tract derived from drug release measurements and plasma concentrations | 3/14/2009 3:12:39 PM | Poster: Methodology- Other topics | |
Optimal design for models with semi-parametric distributions | 3/13/2009 4:21:44 PM | Poster: Methodology- Design | |
Characterizing time to conversion to sinus rhythm under digoxin and placebo in acute atrial fibrillation | 3/12/2009 10:28:18 AM | Poster: Applications- CVS | |
The Influence of the Time Course of CD4 and Viral Load on Clinical Outcome Events Before and During Antiretroviral Therapy | 3/15/2009 11:46:28 AM | Oral Presentation: Methodology | |
Andrew C. Hooker, Joakim Nyberg, Richard Höglund, Martin Bergstrand and Mats O. Karlsson | Autocorrelation reduces sample time clustering in optimal design | 3/16/2009 4:41:31 AM | Poster: Methodology- Design |
Time to Event modeling of dropout event in clinical trials | 3/16/2009 4:45:11 AM | Oral Presentation: Other topics | |
Pharmacokinetic Model for Losartan Administered to Young Mexican Healthy Volunteers. | 1/15/2009 9:31:20 AM | Poster: Applications- CVS | |
Confirmatory Phase III Population Pharmacokinetic Analysis | 3/14/2009 4:37:06 PM | Oral Presentation: Other topics | |
Estimating Transformations for Population Models of Continuous, Closed Interval Data | 2/27/2009 8:05:56 PM | Oral Presentation: Methodology | |
Population PK modeling of Midazolam in Children; The effect of age versus other covariates | 3/13/2009 1:47:59 PM | Poster: Methodology- Other topics | |
Simcyp Simulator - a comprehensive platform and database for mechanistic modelling and simulation of drug absorption, tissue distribution, metabolism, transport and elimination in healthy and disease populations using in vitro knowledge | 5/9/2009 8:02:28 PM | Software demonstration | |
The MM-USCPACK software for nonparametric adaptive grid (NPAG) population PK/PD modeling, and the MM-USCPACK clinical software for individualized drug regimens. | 1/23/2009 5:04:52 AM | Software demonstration | |
Optimal Stochastic Control Of Drug Dosage Regimens | 1/15/2009 9:27:16 AM | Poster: Applications- Other topics | |
Pharmacokinetics of high-dose methotrexate in adults and children | 3/14/2009 6:41:26 PM | Poster: Applications- Oncology | |
Use of PBPK modelling in drug discovery at Pfizer | 3/11/2009 6:46:44 PM | Poster: Methodology- PBPK | |
A pharmacokinetic-pharmacodynamic model for ECG pattern changes in dog and monkey | 3/11/2009 1:31:52 PM | Poster: Applications- CVS | |
Helene Karcher (1), Ken Abrams (2), Alan Slade (2), Olivier Luttringer (1) | Interpreting QT in a Patient Population After Surgical Intervention | 3/11/2009 2:26:13 PM | Poster: Applications- Other topics |
Harnessing clinical knowledge on ligand-targeting drug to develop a new compound targeting the associated receptor : an example of model-based biologics design in pre-clinical development | 3/11/2009 2:15:19 PM | Poster: Applications- Biologicals/vaccines | |
Modeling of hypertension in response to anti-angiogenic therapy | 3/1/2009 5:10:58 PM | Oral Presentation: Clinical Applications | |
Hierarchical-likelihood approach for nonlinear mixed-effect models | 4/3/2009 9:12:24 AM | Poster: Methodology- Algorithms | |
Modeling the permeability of Fosfomycin into Abscess Fluid | 3/13/2009 7:42:55 PM | Poster: Applications- Anti-infectives | |
Massimo Cella (1), Frank L. Kloprogge(1), Meindert Danhof (1) and Oscar Della Pasqua (1,2) | Comparative analysis of scaling methods for dose selection in paediatric indications | 3/15/2009 8:09:49 PM | Poster: Methodology- Design |
Are Children Small Adults: What can modeling offer to (clinical) practice? | 6/19/2009 10:33:38 AM | Oral Presentation: Pediatrics | |
Comparison of Parameter Estimates for One Special Model of Survival Curves for Sample with Interval Censoring | 3/15/2009 12:15:13 AM | Poster: Methodology- Model evaluation | |
H. Kramer1, A. Zandvliet1, R. Berg2, HJ Streefkerk4, P. Grobara3, P Peeters2, T Kerbusch1 | Phase II dose selection for a hypothetical novel Direct Thrombin Inhibitor (DTI): an integrated approach using experimental and literature data. | 3/16/2009 3:53:55 PM | Poster: Methodology- Other topics |
Evaluation of morphine pharmacokinetic models in neonates and infants. | 3/12/2009 9:48:02 AM | Poster: Methodology- Model evaluation | |
Receptor Mediated Disposition PK/PD Model of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations. | 3/12/2009 4:00:37 PM | Poster: Applications- Biologicals/vaccines | |
New parametric model for survival fitting | 3/13/2009 3:25:38 PM | Poster: Methodology- Model evaluation | |
A 3D mechanical model of the gastric esophageal junction: model-based assessment of muscle stretch tension in the gastric smooth muscle with emphasis to reflux disease | 3/13/2009 6:11:50 PM | Poster: Applications- Other topics | |
Andreas Kuttler, Thomas Dimke, Steven Kern, Gabriel Helmlinger, Luca A. Finelli | A 3D Computational Model Of Cerebrospinal Fluid Dynamics For Predictive Biosimulation | 3/13/2009 6:02:15 PM | Oral Presentation: Other topics |
Implementation of a NONMEM cluster and add-ons within UCB | 3/13/2009 8:34:47 AM | Poster: Methodology- Other topics | |
Exposure-Response Modeling of the ACR50 Score in Rheumatoid Arthritis Patients Treated with Certolizumab Pegol. | 3/14/2009 8:58:47 AM | Poster: Applications- Biologicals/vaccines | |
A new exact test to globally assess a population PK and/or PD model | 3/15/2009 5:28:48 PM | Oral Presentation: Methodology | |
Impact of Dosing Regimens on Dropout Across Pregabalin Trials in the Treatment of Generalized Anxiety Disorder: Model Refinements and External Validation | 3/10/2009 4:35:08 PM | Poster: Methodology- Model evaluation | |
Integrated analysis of Human PET data across multiple brain regions and receptors to make inferences from limited data. | 3/15/2009 12:16:06 PM | Poster: Applications- CNS | |
Analysing population PK/PD data with MONOLIX 3.1 | 3/15/2009 4:54:33 PM | Software demonstration | |
Population pharmacokinetics of Ceftriaxone in intensive care unit (ICU) adult patients | 3/13/2009 9:31:57 AM | Poster: Applications- Anti-infectives | |
Estimation of Population Pharmacokinetic Measures and Selection of Sampling Times | 3/12/2009 7:49:25 PM | Poster: Methodology- Design | |
L. Liefaard (1), D. Huntjens (2), A. Vermeulen (2) & H. Drenth (1) | Modelling non-linear dose-dependent absorption profiles after oral prolonged release formulations | 3/19/2009 11:48:28 AM | Poster: Applications- Other topics |
Pharmacokinetic/Pharmacodynamic Modeling of Sunitinib in Healthy Volunteers | 3/13/2009 3:45:13 PM | Poster: Applications- Oncology | |
Modeling of Red Blood Cell (RBC) Lifespan (LS) in a Hematologically Normal Population | 6/18/2009 9:02:47 PM | Oral Presentation: Clinical Applications | |
Rocío Lledó-García, Stefanie Hennig, Joakim Nyberg, Andrew C. Hooker & Mats O. Karlsson | Seeking ethically attractive dose-finding designs for narrow therapeutic index drugs | 3/12/2009 5:01:40 PM | Poster: Methodology- Design |
I. Locatelli (1), B. Perissutti (2), D Voinovich (2), A. Mrhar (1), I. Grabnar (1) | Population Pharmacokinetic Analysis of Silymarin Bioavailability in Rats | 3/13/2009 9:09:55 PM | Poster: Applications- Other topics |
Michael Looby, Guenther Kaiser, Beatrice Abrams and Bill Sallas | Elucidation of the optimal dosing scheme of an antiviral drug in children | 3/15/2009 8:22:06 PM | Oral Presentation: Pediatrics |
On the ability to predict free ligand suppression when free ligand assays are not available or impossible | 3/14/2009 1:21:38 PM | Poster: Applications- Biologicals/vaccines | |
Pharmacokinetics of canakinumab and pharmacodynamics of IL-1β binding in patients with cryopyrin associated periodic fever syndromes | 3/14/2009 12:25:55 PM | Poster: Applications- Biologicals/vaccines | |
Relationship between omalizumab pharmacokinetics and IgE pharmacodynamics in adult and pediatric patients with moderate to severe persistent allergic (IgE-mediated) asthma | 3/14/2009 1:11:19 PM | Poster: Applications- Biologicals/vaccines | |
Omalizumab (Xolair) may normalise IgE production rate in patients with moderate-to-severe atopic asthma | 3/14/2009 1:36:10 PM | Poster: Applications- Biologicals/vaccines | |
Guangli Ma1, Bo L Olsson2, Johan Rosenborg2, Mats O. Karlsson1 | Quantifying Lung Function Progression in Asthma | 3/13/2009 5:31:08 PM | Poster: Applications- Other topics |
Rujia Xie1, Rosalin Arends2, Stephen Olson2 , and Scott Marshall1 | Population Pharmacokinetic/Pharmacodynamic (PK/PD) Analysis of the Effect of Tanezumab on Overall Daily Pain Score Data in Adults with Moderate-to-Severe Pain due to Osteoarthritis of the Knee | 3/13/2009 5:30:53 PM | Poster: Applications- Biologicals/vaccines |
Amélie Marsot (1), Edith Ramain (2), Olivier Perus (2), Nicolas Simon (1) | External validation of pharmacokinetic population model of alfentanil in obese patients. | 2/25/2009 4:04:08 PM | Poster: Applications- CNS |
Population pharmacokinetic model for Ritonavir (RTV) in HIV-infected patients treated with Lopinavir (LPV)/RTV (KaletraTM) | 3/15/2009 8:57:16 PM | Poster: Applications- Anti-infectives | |
Infrastructure development for building, maintaining and modeling indication- specific summary-level literature databases to support model based drug development. | 2/26/2009 3:38:15 PM | Poster: Methodology- Other topics | |
M. Lavielle (1), A. Samson (2), A.K. Fermin (3) and F. Mentré (4) | Parameter estimation of long-term HIV dynamic model in the COPHAR2 – ANRS 111 trial using MONOLIX | 3/13/2009 8:11:53 AM | Poster: Applications- Anti-infectives |
A.H. Mohammadpour(1), S. Rezaee(2), S. Sadray(3), P. Ghaeli(4) | Population pharmacokinetics of carbamazepine in Iranian epileptic and manic patients | 2/25/2009 5:56:59 PM | Poster: Applications- CNS |
Musuamba F(1), Mourad M(2), Haufroid V(3), Wallemacq P(4), Verbeeck RK(1) | Multivariate and Population Pharmacokinetic Analyses for Tacrolimus Area Under The Concentration-Time Curve Prediction in De Novo Renal Transplant Recipients | 3/16/2009 12:59:58 AM | Poster: Applications- Other topics |
Time of Drug Administration, Genetic Polymorphism and Analytical Method Influence Tacrolimus Pharmacokinetics: A Population Pharmacokinetic Approach | 3/15/2009 7:13:18 AM | Poster: Applications- Other topics | |
Bioequivalence Trials Simulation to Select the Best Analyte for Drugs with Presystemic Intestinal and Hepatic Metabolism. | 3/13/2009 6:46:52 PM | Poster: Methodology- Other topics | |
Exposure-Response Analysis of a DPP-IV Inhibitor, PF-00734200 on HbA1c in Type 2 Diabetic Subjects on Stable Metformin Treatment | 3/10/2009 7:08:53 PM | Poster: Applications- Endocrine | |
M. Neely (1,2,3), T. Rushing (4), A. Kovacs (3), R. Jelliffe (2), J. Hoffman (1) | Voriconazole Population Pharmacokinetics and Pharmacodynamics in Children | 3/10/2009 11:03:35 PM | Poster: Applications- Anti-infectives |
Assessment of NONMEM and WinBUGS performances when estimating power and sigmoid Emax models | 3/13/2009 7:24:02 PM | Poster: Methodology- Model evaluation | |
Validation of a neutropenia PK/PD model built from intravenous vinflunine and its application to design phase I trials with oral vinflunine | 3/13/2009 10:54:15 AM | Poster: Applications- Oncology | |
Using short-term evidence to predict six-month outcomes in clinical trials of signs and symptoms in rheumatoid arthritis | 3/13/2009 1:51:55 PM | Poster: Methodology- Model evaluation | |
Population optimal experimental design for discrete type data | 3/1/2009 8:57:10 PM | Oral Presentation: Design | |
Sample Size/Power Calculations for Population Pharmacodynamic Experiments Involving Repeated Count Measurements | 3/16/2009 12:34:22 AM | Poster: Methodology- Design | |
Population pharmacokinetics of Ropivacaine and Bupivacaine after loco-regional administration as anesthetic in hip or knee replacement surgery. | 3/13/2009 6:52:49 PM | Poster: Applications- Other topics | |
Population Pharmacokinetics and Pharmacodynamics of Hydroxyurea in Sickle Cell Anemia Patients, In Silico Comparison of Two Dosing Regimens | 3/13/2009 11:34:01 PM | Poster: Applications- Other topics | |
The pharmacodynamics of isoflurane in children using Bispectral index and composite auditory evoked potentials | 3/13/2009 8:03:03 PM | Poster: Applications- CNS | |
Klas J. Petersson(1), An M. Vermeulen(2), Lena E. Friberg(1) | Could prolactin levels be a more informative predictor for clinical effect of D2-receptor antagonists than drug concentrations in the treatment of schizophrenia? | 3/13/2009 12:28:32 PM | Poster: Applications- CNS |
Introducing the renin-angiotensin-aldosterone (RAAS) hypertension platform: an in-silico approach to evaluating efficacy of RAAS modulating drugs on blood-pressure control and end-organ protection | 3/14/2009 1:35:04 PM | Poster: Applications- CVS | |
E. Pigeolet (1), P. Wiczling (3), P. Lowe (1), S. Balser (2), A. Berghout (2) and W. Krzyzanski (4) | Artefactual inflation of pharmacokinetic difference between two Granulocyte Colony Stimulating Factor (G-CSF) drug products by non compartmental analysis. | 3/13/2009 8:13:11 AM | Poster: Applications- Biologicals/vaccines |
Gregory Pinault, Aurelie Gautier, Goonaseelan Pillai, Jean-Louis Steimer, Vincent Buchheit | Quality, Efficiency and Industrialisation Initiatives during the evolution of a dedicated SAS Programming Group | 3/12/2009 4:43:20 PM | Poster: Applications- Other topics |
Celine Pitou, PharmD1; Inaki Troconiz, PhD2; Sophie Glatt, PhD3 | Modelling of PK/Efficacy/Toxicity in rats to help design a First Human Dose for a cell cycle inhibitor X | 3/9/2009 12:42:34 PM | Poster: Applications- Oncology |
Eleven ordered categories data: which modelling options? | 3/15/2009 4:39:19 PM | Poster: Methodology- Model evaluation | |
New models for handling correlated underdispersed Likert pain scores | 3/15/2009 4:35:59 PM | Poster: Methodology- Algorithms | |
C.Pobel(1), M.Guery(1), G.Herbin(1), E.Kiep(1), C.Donamaria(2) | Time to event models of survival in cancer of pancreas : confirmation of explanatory variables pre-selected by bootstrap analysis. | 3/15/2009 9:51:28 PM | Poster: Applications- Oncology |
Is Calcineurin Activity Useful as a Biomarker to Optimize Cyclosporine A Therapy in Renal Transplant Recipients? | 2/27/2009 2:24:38 PM | Poster: Applications- Other topics | |
N.H. Prins (1), F. Jonsson (1), S. Haughie (2), P. Johnson (2), S.W. Martin (2) | Comparison of a maximum likelihood versus a full bayesian method to jointly model individual with summary level data | 3/15/2009 2:48:40 PM | Poster: Methodology- Algorithms |
N.H. Prins (1), A. Cleton (2), M.O. Magnusson (2) , P. Johnson (2), A. Heatherington (2) | Characterization of the population pharmacokinetics of UK-369,003 using a semi-mechanistic model | 3/15/2009 2:42:13 PM | Poster: Methodology- PBPK |
N.H. Prins (1), M. Green (1), S. Haughie (2), P. Johnson (2), S. W. Martin (2) | Use of model based meta-analysis combining patient-level with summary-level data using multilevel random effects to provide a quantitative assessment of the clinical efficacy (IPSS) profile and competitive positioning of a PDE5 inhibitor (UK369,003) for the treatment of benign prostatic hyperplasia (BPH). | 3/15/2009 3:01:43 PM | Poster: Applications- Other topics |
Angelica L. Quartino (1), Lena E. Friberg (1), Sharon D. Baker (2) and Mats O. Karlsson (1) | A semi-mechanistic myelosuppression model of docetaxel treatment in liver impaired patients | 3/13/2009 2:05:23 PM | Poster: Applications- Oncology |
A physiologically based pharmacodynamic model of the Renin-Angiotensin-Aldosterone-System | 3/13/2009 4:25:30 PM | Poster: Applications- Endocrine | |
Patanjali Ravva (1), Jonathan French (1), Sarah Dubrava (2) and Hélène M Faessel (3) | Enhanced Clinical Trial Design of a Proof-of-Concept Study via Bayesian simulation analyses | 3/14/2009 5:19:25 PM | Poster: Methodology- Design |
Population Pharmacokinetic-Pharmacodynamic Analysis of Weight Loss Efficacy of CP-945,598 in Adult Obese Subjects | 3/13/2009 6:19:43 PM | Poster: Applications- CVS | |
Using desirability indices for decision making in drug development | 3/12/2009 2:11:36 PM | Poster: Methodology- Other topics | |
S. Rezaee(1), T. Safarnavadeh(2), H. Khalili(2), S. Dashti(2), K. Daneshjoo(3), S. Sadray(4) | Population Pharmacokinetics of Vancomycin in Iranian Paediatric Patients | 3/14/2009 11:41:28 AM | Poster: Applications- Anti-infectives |
B. Ribba, E. Watkin, M. Tod, P. Girard, B. You, B. Tranchand, E. Grenier, G. Freyer | Estimating the kinetic parameters of vascular tumor growth models to optimize anti-angiogenesis drugs delivery | 3/13/2009 9:44:19 AM | Oral Presentation: Methodology |
Elba Romero1, Josep-María Cendrós 2, Concepción Peraire2, Rosendo Obach2, and Iñaki F. Trocóniz.1 | Impact of pharmacokinetic information reported as being below limit of quantification on the prediction of important response endpoints. | 3/13/2009 5:37:21 PM | Poster: Applications- Endocrine |
Maximum likelihood estimation in nonlinear mixed effect models: Adaptive Gaussian Quadrature by sparse grid sampling | 3/14/2009 8:32:51 AM | Oral Presentation: Methodology | |
A. Russu (1), G. De Nicolao (1), I. Poggesi (2), R. Gomeni (2) | Dose escalation studies: a comparison among Bayesian models | 3/14/2009 8:58:45 PM | Poster: Methodology- Model evaluation |
Matching PBPK and NONMEM pharmacokinetics descriptions to understand and extrapolate - case study ciprofloxacin | 3/13/2009 7:50:07 PM | Poster: Methodology- Other topics | |
Population Pharmacokinetics of Lopinavir (Kaletra) in HIV-Infected Patients | 3/14/2009 2:25:33 PM | Poster: Applications- Anti-infectives | |
A new SAEM algorithm for ordered-categorical and count data models: implementation and evaluation | 3/13/2009 12:10:44 AM | Oral Presentation: Methodology | |
Optimal Design for the improvement of sampling schedules of microdialysis studies. | 3/10/2009 5:47:34 PM | Poster: Methodology- Design | |
An integrated model for glucose-insulin regulation to describe oral glucose tolerance test data in healthy volunteers | 3/1/2009 2:31:52 PM | Poster: Applications- Endocrine | |
Prediction of remifentanil metabolic ratio using sparse data collected during non-steady-state infusion with rapidly changing rate | 3/13/2009 8:16:07 PM | Poster: Applications- CNS | |
H. Abou hammoud(1), N. Simon(2), S. Urien(3), B. Riou(4), P. Lechat(1), F. Aubrun (5) | Population Kinetic Pharmacodynamic and Logistic Regression Analysis of Intravenous Morphine Titration in Immediate Postoperative Period | 3/3/2009 6:03:01 PM | Poster: Applications- CNS |
MSToolkit – An R library for simulating and evaluating clinical trial designs and scenarios | 3/12/2009 6:04:25 PM | Poster: Methodology- Design | |
Mechanistic pharmacokinetic enzyme model for the characterisation of rifampicin pharmacokinetics in South African pulmonary TB infected adults | 3/13/2009 8:35:09 PM | Poster: Applications- Anti-infectives | |
N. Snelder (2), T. van Steeg (2), B. Ploeger (2), N. Attkins (1), P. van der Graaf (1) | Safety pharmacology screening using a standardized population pharmacokinetic pharmacodynamic modelling approach | 3/13/2009 10:07:31 AM | Poster: Applications- Other topics |
N. Snelder (2), C. Diack (2), N. Benson (1), B. Ploeger (2), P. van der Graaf (1) | A proposal for implementation of the Markov property into a continuous time transition state model in NONMEM | 3/13/2009 10:10:10 AM | Poster: Methodology- Other topics |
Alexandre SOSTELLY (1, 2), Emilie HÉNIN (1), Benoit YOU (2), Pascal GIRARD (2), Mats O KARLSSON (1) | Simultaneous modelling of PSA production in Prostatic Benign Hyperplasia (PBH) and prostatic adenocarcinoma patients treated by prostate surgery | 3/11/2009 4:16:32 PM | Poster: Applications- Oncology |
Elena Soto(1), Alexander Staab(2), Gerd Munzert(2), Holger Fritsch(2), and Iñaki F. Trocóniz(1) | Prediction of haematological effects of a new combination of anticancer drugs, BI 2536 (a PLK1 inhibitor) and pemetrexed, using a semi-mechanistic population model for neutropenia | 2/27/2009 7:03:29 PM | Oral Presentation : Lewis Sheiner Student Session |
Population Pharmacokinetic Modelling of Esomeprazole Nonlinearity | 3/13/2009 8:14:43 PM | Poster: Applications- Other topics | |
Genotyped versus phenotyped dosing to account for UGT polymorphism of the novel PPAR agonist sipoglitazar | 3/14/2009 7:01:06 PM | Oral Presentation: Clinical Applications | |
Ashley Strougo(1,2); Walter Krauwinkel(1); Meindert Danhof(2); Jan Freijer(1) | Mechanism-based pharmacokinetic modelling to describe the effect of protein binding on the pharmacokinetics of solifenacin | 3/14/2009 9:38:10 AM | Poster: Methodology- Other topics |
A. Mohamed (1), E.I. Nielsen (1), O. Cars(2) and L.E. Friberg(1). | Pharmacokinetic/Pharmacodynamic Modeling of Adaptive Resistance of Gentamicin | 3/15/2009 6:24:25 AM | Poster: Applications- Anti-infectives |
Model-based optimization of rituximab dosing regimen in follicular non-Hogdkin lymphoma | 3/12/2009 6:30:33 PM | Oral Presentation: Clinical Applications | |
Population pharmacokinetics of artesunate and dihydroartesunate in adults and children following administration of a fixed dose combination formulation of chlorproguanil-dapsone-artesunate | 3/13/2009 10:12:35 AM | Poster: Applications- Anti-infectives | |
M.N. Trame (1), I.H. Bartelink (2), J. Boos (3), J.J. Boelens (2), G. Hempel (1,3) | Population Pharmacokinetics of Dimethylacetamide in Children During Once-daily and Standard IV Busulfan Administration | 3/13/2009 3:25:45 PM | Poster: Applications- Oncology |
Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based pharmacokinetic model for treatment strategy improvement and prediction of individual responses. | 1/21/2009 4:02:24 PM | Oral Presentation: Clinical Applications | |
Comprehensive Virtual Patient Platform Implemented For Anti-Angiogentic Drugs Development | 5/4/2009 11:18:27 AM | Poster: Methodology- Algorithms | |
Novel graphical diagnostics for assessing fit of logistic regression models | 2/26/2009 9:52:03 PM | Oral Presentation : Lewis Sheiner Student Session | |
CSF and Plasma Pharmacokinetics of Flurbiprofen in Children | 3/15/2009 10:58:07 AM | Poster: Applications- CNS | |
J-S van der Walt [1], K Cohen [1], HM McIlleron [1], PJ Smith [1], G Maartens [1], MO Karlsson [2] | Effect of rifampicin-based antitubercular therapy and cotrimoxazole on the population pharmacokinetics of stavudine (d4T) in HIV-1 infected patients | 3/11/2009 3:06:44 PM | Poster: Applications- Anti-infectives |
C. van Kesteren1, M.A. Boroujerdi1, A. Roy1, A. Facius2, M. Danhof1, O.E. Della Pasqua1,3 | Prediction of drug effects using a longitudinal turnover model for FEV1 in patients with chronic obstructive pulmonary disease (COPD). | 3/15/2009 9:47:00 AM | Poster: Applications- Other topics |
Population Pharmacokinetic-pharmacodynamic modeling of the Analgesic Effects of Lumiracoxib, a selective inhibitor of the enzyme COX2 in the Rat | 3/3/2009 12:29:54 PM | Poster: Methodology- Other topics | |
Pipeline Pilot - Data Integration, Analysis, and Reporting Platform | 3/11/2009 2:47:57 PM | Software demonstration | |
A physiology-based pharmacokinetic model describing the disposition of a novel selective anxiolytic drug afobazole and its metabolites in rats. | 3/14/2009 12:28:54 PM | Poster: Methodology- PBPK | |
Effect of Valproic Acid Daily Dose on its Clearance in Adult Patients with Epilepsy – Population analysis of TDM data | 3/11/2009 11:23:44 AM | Poster: Applications- CNS | |
Estimation of cortical amyloid beta turnover rates | 3/13/2009 9:06:57 AM | Poster: Applications- CNS | |
A comprehensive model for the coagulation network in humans | 3/3/2009 7:15:32 AM | Poster: Applications- Coagulation | |
Model Based Neutrophil Guided Dose Adaptation in Chemotherapy | 3/3/2009 5:16:07 PM | Poster: Applications- Oncology | |
Standardized Visual Predictive Check – How and When to used it in Model Evaluation | 3/11/2009 8:57:46 PM | Oral Presentation: Methodology | |
Population PK modeling and simulation to select a dosing schedule in Phase II trials for a novel TKI agent with time-dependent and nonlinear PK | 3/14/2009 5:15:42 AM | Poster: Applications- Oncology | |
Phoenix NLME and Phoenix | 6/5/2009 2:51:23 PM | Software demonstration | |
Census: NLME project management for NONMEM | 3/4/2009 10:41:24 AM | Software demonstration | |
Jason H. Williams (1), Bhuvaneswari Jayaraman (1), Richard S. Finkel (2), Jeffrey S. Barrett (1) | Bayesian Network Approach to Modeling Spinal Muscular Atrophy Populations | 3/15/2009 10:50:44 PM | Poster: Applications- Other topics |
Bayesian Adaptive Designs for Phase IIb Dose-ranging Study in Rheumatoid Arthritis (RA) | 3/9/2009 11:51:09 AM | Poster: Methodology- Design | |
Validation of in vivo Mouse PK Assay by Mixed Effects Modelling: Estimation of between-study variability. | 3/13/2009 10:54:36 AM | Poster: Methodology- Other topics | |
Use of Eltrombopag Exposure-Platelet Response Relationship for Dose Optimization in Patients with Chronic HCV-Infection with and without Interferon | 3/11/2009 2:52:33 PM | Poster: Applications- Anti-infectives |
